Leupo 22.5mg Injection 1ml Allschoolabs -

Description

INTRODUCTION
LEUPO 22.5MG INJECTION contains Leuprolide which belongs to the group of medicines called Gonadotropin Releasing Hormone (GnRH) Agonist. It is used for palliative treatment (relieving symptoms and minimising the associated suffering) of advanced prostatic cancer.
Advanced prostatic cancer is a cancer (abnormal cell multiplication and differentiation) that originates in the prostate gland and spreads to the other parts of the body. It is characterized by the symptoms such as painful urination, decreased urine pressure, blood in the semen, bone pain, leg swelling, and weakness.
Do not receive LEUPO 22.5MG INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs.
Before receiving this medicine, inform your doctor if you have liver impairment, kidney impairment, congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, metastatic vertebral lesions, urinary tract obstruction, or diabetes.
Before receiving this medicine, inform your doctor if you have a history of seizures, epilepsy, cerebrovascular disorders, or central nervous system anomalies/tumours. LEUPO 22.5MG INJECTION is not recommended for use in pregnant women, breastfeeding women, and children.
It should be used with caution in elderly patients (aged above 65 years). Consult your doctor before receiving.
The most common side effects associated with the use of LEUPO 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in upper respiratory tract, and fatigue. Consult your doctor if any of these side effects worsens.
USES OF LEUPO 22.5MG INJECTION

Used for palliative treatment (relieving symptoms and minimize the associated suffering) of advanced prostatic cancer

HOW LEUPO 22.5MG INJECTION WORKS
LEUPO 22.5MG INJECTION helps in palliative treatment of advanced prostatic cancer where leuprolide works by blocking the secretion of gonadotropin releasing hormone (GnRH) following an initial stimulation, resulting in suppression of ovarian and testicular steroidogenesis (process of synthesis of steroid hormones), thereby relieving the symptoms associated with increased testosterone levels in advanced prostatic cancer.
DIRECTIONS FOR USE
For intramuscular use:
LEUPO 22.5MG INJECTION will be administered to you only by a doctor or a nurse intramuscularly (into the muscle) or subcutaneously (under the skin). Your doctor will administer the correct dose and duration for you depending upon your age, body weight and disease condition.
SIDE EFFECTS OF LEUPO 22.5MG INJECTION

COMMON

Hot flashes, sweating

General pain in the body (especially joint pain and back pain)

Pain at the site of injection

Gastrointestinal disorders

Respiratory disorders

Urinary disorders

Shrinking of testicles

Extreme weakness

Headache

Joint disorders

Dizziness

Other sleep disorders

Neuromuscular disorders

Skin reactions

Flu-syndrome

Dehydration

Muscle pain

Sensation of pins and needles

Lethargy

Constipation

Sinus headache

Influenza-like illness including influenza, nasopharyngitis, nasal congestion, upper respiratory tract infection, rhinorrhea, and viral upper respiratory tract infection

Cough

Hemorrhagic cystitis ?

High blood pressure

Rash

Urinary tract infection

Cystitis (an inflammatory condition of bladder)

Decreased haemoglobin

COPD (chronic obstructive pulmonary disease)

Breathlessness especially on exertion

Increased frequency of urination in night

Peripheral/pitting oedema (swelling in legs and feet due to water retention)

Coronary artery disease ( heart disease) characterized by angina (chest pain)

Itching

Hair loss

Pain in testicles

Clamminess

Breast enlargement in males

Reduced libido

RARE
Stop receiving LEUPO 22.5MG INJECTION and contact your doctor if you experience any of the following side effects:???
COPD (chronic obstructive pulmonary disease)

Coronary artery disease (heart disease) is characterized by angina (chest pain)

Cerebrovascular accident/transient ischemic attack (life-threatening events related to impaired heart function)

Pneumonia (a life-threatening lung disease)

Second primary neoplasm (cancer) including basal cell carcinoma, lung neoplasm, bladder transitional cell carcinoma, malignant melanoma, squamous cell carcinoma, non-Hodgkin?s lymphoma

HOW TO MANAGE SIDE EFFECTS
Headache:
Take rest and plenty of water. Avoid taking alcohol and skipping meals. Do not strain your eyes by watching the screen for a long time. Consult your doctor if the condition persists for long or gets worsens.
Dizziness:
Lie down until the dizziness passes and get up slowly. Do not bend down suddenly. Get a lot of rest. Walk slowly and carefully. Take plenty of fluids. Avoid drinking coffee, alcohol, or smoking. Consult your doctor if the condition persists for long or gets worsens.
Constipation:
Try to eat more high-fibre foods such as fresh fruit, vegetables, cereals, and drink plenty of water. Try doing exercise regularly (going for a daily walk or run). If this does not help, inform your doctor for receiving alternate treatments for constipation.
WARNING & PRECAUTIONS

PREGNANCY
LEUPO 22.5MG INJECTION is not recommended for use during pregnancy. Consult your doctor before receiving.
BREASTFEEDING
LEUPO 22.5MG INJECTION is not recommended for use in breastfeeding women as it can pass through milk. Consult your doctor before receiving.
DRIVING AND USING MACHINES
Do not receive LEUPO 22.5MG INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs, or to any of the other ingredients of this medicine.
KIDNEY
LEUPO 22.5MG INJECTION should be used with caution in patients with renal impairment. Consult your doctor before receiving.
LIVER
LEUPO 22.5MG INJECTION should be used with caution in patients with hepatic impairment. Consult your doctor before receiving.
HEART DISEASE
LEUPO 22.5MG INJECTION should be used with caution in patients with congenital long QT syndrome and congestive heart failure only if clearly necessary. Consult your doctor before receiving.
OTHERS
Before receiving LEUPO 22.5MG INJECTION, inform your doctor if you:????
Have frequent electrolyte abnormalities

Have metastatic vertebral lesions

Have urinary tract obstruction

Have diabetes

Have a history of seizure

Have a history of epilepsy

Have a history of cerebrovascular disorders

Have a history of central nervous system anomalies or tumours
Use in pediatrics:
LEUPO 22.5MG INJECTION is not recommended for use in children. Consult your doctor before receiving.
Use in geriatrics:
LEUPO 22.5MG INJECTION should be used with caution in elderly patients (above 65 years). Consult your doctor before receiving.
INTERACTIONS
A. Drug-Drug Interactions
Before receiving LEUPO 22.5MG INJECTION, inform your doctor, if you are taking any of the following medicine:
Medicines that prolong the QT interval (Ex. haloperidol, amiodarone, erythromycin)
Overdosage:
LEUPO 22.5MG INJECTION will be given to you only by a doctor or nurse in a hospital, and so it is unlikely to receive an overdose. If you or anyone else accidentally receives too much of this medicine, consult your doctor immediately or visit the nearby hospital. Symptoms of overdose are shortness of breath, decreased activity, and increased scratching.
SYNOPSIS

Drug :?? Leuprolide

Pharmacological Category :?? Gonadotropin Releasing Hormone (GnRH) Agonist

Therapeutic Indication :?? Palliative treatment for advanced prostatic cancer

Dosage Forms :?? Injection, Injection depot

MORE INFORMATION

Keep LEUPO 22.5MG INJECTION out of reach of children

Store between 2-8?C

FAQs ABOUT LEUPO 22.5MG INJECTION
What LEUPO 22.5MG INJECTION is used for?
LEUPO 22.5MG INJECTION for palliative treatment (relieving symptoms and minimize the associated suffering) of advanced prostatic cancer. Consult your doctor before receiving.
What side effects are seen with LEUPO 22.5MG INJECTION?
The most common side effects associated with the use of LEUPO 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in the upper respiratory tract, and fatigue. Consult your doctor if any of these symptoms worsens.
Who should avoid receiving LEUPO 22.5MG INJECTION?
Do not receive LEUPO 22.5MG INJECTION if you are allergic to leuprolide, GnRH, GnRH agonist analogs. It is not recommended for use in pregnant women, breastfeeding women, and children. Consult your doctor before receiving.
Is LEUPO 22.5MG INJECTION safe to use in children?
LEUPO 22.5MG INJECTION is not recommended for use in children because the safety and effectiveness of this medicine have not been established in this population. Consult your doctor before receiving.
Is LEUPO 22.5MG INJECTION safe to use in pregnant and breastfeeding women?
LEUPO 22.5MG INJECTION is not recommended for use during pregnancy as it may increase the risk for pregnancy loss. It is also not recommended for use in breastfeeding women as it can pass through milk. Consult your doctor before receiving.
What happens if you take more LEUPO 22.5MG INJECTION than your required dose?
LEUPO 22.5MG INJECTION will be given to you only by a doctor or nurse in a hospital, and so it is unlikely to receive an overdose. If you or anyone else accidentally receives too much of this medicine, consult your doctor immediately or visit the nearby hospital. Symptoms of overdose are shortness of breath, decreased activity, and increased scratching.
Is LEUPO 22.5MG INJECTION safe to use in heart patients?
LEUPO 22.5MG INJECTION should be used with caution in patients with congenital long QT syndrome and congestive heart failure only if clearly necessary. Consult your doctor before receiving.
REFERENCES
1. KD. Tripathi. Anterior Pituitary Hormones. Essentials of Medical Pharmacology. Seventh edition. 2013. Page ? 243.
2. Dallas V. Swayzer, Valerie Gerriets. Leuprolide. NIH. National Library of Medicine. National Centre for Biotechnology Information. StatPearls [Internet]. October 2015. [Accessed on 28th November 2022] https://www.ncbi.nlm.nih.gov/books/NBK551662/
3. AbbVie Inc. FDA (Food and Drug Administration). [Revised in June 2014] [Accessed on 28th November 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020517s036_019732s041lbl.pdf
4. Dailymed. ELIGARD- leuprolide acetate. [Revised in April 2019] [Accessed on 28th November 2022] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b78d1919-9dee-44fa-90f9-e0a26d32481d&audience=consumer
PRODUCT DETAILS